JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 06/06/12 -- www.StockCall.com offers free research on Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) from the Biotechnology industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.
Companies in the biotech industry have been working hard this year to develop, market and win FDA and EMA approval for a number of new drugs. Several companies have been focusing on the HIV virus while others have been turning their attention to cancer treatments. Register now to have free access to our reports on the Biotechnology industry, and to do so please click the link below.
StockCall.com is an online platform where investors doing their due-diligence on the Biotechnology industry can have easy and free access to our analyst research and opinions on Celgene Corporation and Gilead Sciences Inc.; investors and shareholders of these companies can simply register for our complimentary reports by clicking on the link below.
One company that has a number of oncology products in its portfolio is Celgene Corporation. In its 1st quarter report, the company missed some analysts' earnings expectations but did manage to post adjusted earnings per share of $0.96. The company has several products that will be presented to the EMA and FDA for approval moving forward. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.
FDA approval can make or break biotech companies, especially considering the amount of capital that is necessary during the research and development stage. Gilead Sciences Inc. recently took a step in the right direction, as its HIV combination pill Quad received an approval recommendation from an FDA advisory panel. It is anticipated that the final decision will be made in late August.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
William T. Knight